(3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: A conformationally restricted analogue of the NRr2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidino)-1- propanol

Journal of Medicinal Chemistry

Volumn 41, Issue 7, 1998, Pages 1172-1184

  Butler, Todd W ^a   Blake, James F ^a   Bordner, Jon ^a   Butler, Paul ^a   Chenard, Bertrand L ^a   Collins, Mary A ^a   DeCosta, Debra ^a   Ducat, Mary J ^a   Eisenhard, Michael E ^a   Menniti, Frank S ^a   Pagnozzi, Martin J ^a   Sands, Steven B ^a   Segelstein, Barbara E ^a   Volberg, Walter ^a   White, W Frost ^a   Zhao, Dayao ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (4 FLUOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL]CHROMAN 4,7 DIOL; CP 283097; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRAXOPRODIL; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG SELECTIVITY; RACEMIC MIXTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

EID: 14444271319     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9707986     Document Type: Article

References (62)

1. Menniti, F.; Chenard, B.; Collins, M.; Ducat, M.; Shalaby, I.; White, F. CP-101,606, a Potent Neuroprotectant Selective for Forebrain Neurons. Eur. J. Pharmacol. 1997, 331, 117-126.
2. Except where indicated, all new compounds were prepared as racemates. The stereochemistry illustrated for all new compounds was chosen based on the absolute stereochemistry of 12a as defined by X-ray structure analysis of its p-bromobenzyl ether.
3. Chenard, B. L.; Bordner, J.; Butler, T. W.; Chambers, L. K.; Collins, M. A.; DeCosta, D. L.; Ducat, M. F.; Dumont, M. L.; Fox, C. B.; Mena, E. E.: Menniti, F. S.; Neilsen, J.; Pagnozzi, M. J.; Richter, K. E. G.; Ronau, R. T.; Shalaby, I. A.; Stemple, J. Z.; White, W. F. (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-Aspartate Responses. J. Med. Chem. 1995, 38, 3138-3145.
4. Winter, C. W.; Hamilton, C. S. Substituted Chromones. J. Am. Chem. Soc. 1952, 74, 3999-4001. Colonge, J.; Guyot, A. No 44.-Etude sur les chromanones-4, III. Alcoylation et bromuration des chromanones: passage aux chromones. Bull. Chim. Soc. Fr. 1958, 329-334. auf dem Keller, H. H.; Zymalkowski, F. 3-Amino-chromanole-(4) als potentialle Sympathomimetika. Arch. Pharm. (Weinheim) 1971, 304, 543-554.
5. Winter, C. W.; Hamilton, C. S. Substituted Chromones. J. Am. Chem. Soc. 1952, 74, 3999-4001. Colonge, J.; Guyot, A. No 44.-Etude sur les chromanones-4, III. Alcoylation et bromuration des chromanones: passage aux chromones. Bull. Chim. Soc. Fr. 1958, 329-334. auf dem Keller, H. H.; Zymalkowski, F. 3-Amino-chromanole-(4) als potentialle Sympathomimetika. Arch. Pharm. (Weinheim) 1971, 304, 543-554.
6. Winter, C. W.; Hamilton, C. S. Substituted Chromones. J. Am. Chem. Soc. 1952, 74, 3999-4001. Colonge, J.; Guyot, A. No 44.-Etude sur les chromanones-4, III. Alcoylation et bromuration des chromanones: passage aux chromones. Bull. Chim. Soc. Fr. 1958, 329-334. auf dem Keller, H. H.; Zymalkowski, F. 3-Amino-chromanole-(4) als potentialle Sympathomimetika. Arch. Pharm. (Weinheim) 1971, 304, 543-554.
7. It has been reported that 3-bromochromone and 3-bromothiochromone may react with nucleophiles to form a variety of products resulting from initial Michael addition and subsequent rearrangement, pyranone ring opening, or pyranone ring contraction. See, for example: Gammill, R. B.; Nash, S. A.; Mizsak, S. A. The Addition of Amines to 3-Bromochromone and 6-Bromofurochromone. An unexpected Ring Contraction of the Pyrone Ring. Tetrahedron Lett. 1983, 24, 3435-3438. Gammill, R. B.; Nash, S. A.; Bell, L. T.; Watt, W. A Novel Entry to Substituted Chromones and Furochromones Through Cyclopropane Intermediates. Tetrahedron Lett. 1992, 33, 997-1000. Nakazumi, H.; Watanabe, S.; Maeda, K.; Kitao, T. Synthesis of 2-(Aminomethylene)-2H,3H-1-benzothiophene-3-one form 3-Bromo-4H-1-benzothiopyran-4-one as a new Donor-Acceptor Chromophore. Chem. Lett. 1990, 679-682.
8. It has been reported that 3-bromochromone and 3-bromothiochromone may react with nucleophiles to form a variety of products resulting from initial Michael addition and subsequent rearrangement, pyranone ring opening, or pyranone ring contraction. See, for example: Gammill, R. B.; Nash, S. A.; Mizsak, S. A. The Addition of Amines to 3-Bromochromone and 6-Bromofurochromone. An unexpected Ring Contraction of the Pyrone Ring. Tetrahedron Lett. 1983, 24, 3435-3438. Gammill, R. B.; Nash, S. A.; Bell, L. T.; Watt, W. A Novel Entry to Substituted Chromones and Furochromones Through Cyclopropane Intermediates. Tetrahedron Lett. 1992, 33, 997-1000. Nakazumi, H.; Watanabe, S.; Maeda, K.; Kitao, T. Synthesis of 2-(Aminomethylene)-2H,3H-1-benzothiophene-3-one form 3-Bromo-4H-1-benzothiopyran-4-one as a new Donor-Acceptor Chromophore. Chem. Lett. 1990, 679-682.
9. It has been reported that 3-bromochromone and 3-bromothiochromone may react with nucleophiles to form a variety of products resulting from initial Michael addition and subsequent rearrangement, pyranone ring opening, or pyranone ring contraction. See, for example: Gammill, R. B.; Nash, S. A.; Mizsak, S. A. The Addition of Amines to 3-Bromochromone and 6-Bromofurochromone. An unexpected Ring Contraction of the Pyrone Ring. Tetrahedron Lett. 1983, 24, 3435-3438. Gammill, R. B.; Nash, S. A.; Bell, L. T.; Watt, W. A Novel Entry to Substituted Chromones and Furochromones Through Cyclopropane Intermediates. Tetrahedron Lett. 1992, 33, 997-1000. Nakazumi, H.; Watanabe, S.; Maeda, K.; Kitao, T. Synthesis of 2-(Aminomethylene)-2H,3H-1-benzothiophene-3-one form 3-Bromo-4H-1-benzothiopyran-4-one as a new Donor-Acceptor Chromophore. Chem. Lett. 1990, 679-682.
10. We also attempted to prepare the C-4 acetoxy product by acylation of the C-7 TIPS-protected phenol 29. In this case fluoride deprotection afforded only 10a and its trans epimer 10b. This is consistent with the proposed rapid formation of a quinone methide when a good C-4 leaving group is present and capture with water upon workup. The same result was observed when we attempted to introduce a C-4 benzoyl group.
11. 2). Formation and Application to Organic Synthesis. J. Am. Chem. Soc. 1965, 87, 1353-1364.
12. The trans isomer 36b was not obtained 100% pure. Stereochemical assignments for 36a and 36b followed from the NMR decoupling experiments below. (Left) Irradiation at 5.31 ppm results in loss of the 1.6-Hz coupling to the proton at 0.96 ppm. (Right) Irradiation at 4.32 ppm results in loss of the 1.3-Hz coupling to the proton at 5.06 ppm, loss of the 3.9-Hz coupling to the proton at 1,08 ppm, and loss of the 7.6-Hz coupling to proton at 0.99 ppm.
13. 14C]CP-101, 606. J. Labelled Compas. Radiopharm. 1997, XXXIX, 973-985.
14. Shalaby, I. A.; Chenard, B. L.; Prochniak, M. A.; Butler, T. W. Neuroprotective Effects of the N-Methyl-D-Aspartate Receptor Antagonists Ifenprodil and SL 82.0715 on Hippocampal Cells in Culture. J. Pharmacol. Exp. Ther. 1992, 260, 925-932.
15. 3H]prazosin binding assay, see: Greengrass, P.; Bremner, R. Binding Characteristics of Prazosin-H-3 to Rat-Brain Alpha-Adrenergic Receptors. Eur. J. Pharmacol. 1979, 55, 323-326.
16. See ref 3 and Chenard, B. L.; Shalaby, I. A.; Koe, B. K.; Ronau, R. T.; Butler, T. W.; Prochnick, M. A.; Schmidt, A. W.; Fox, C. B. Separation of α1-Adrenergic and N-Methyl-D-Aspartate Antagonist Activity in a Series of Ifenprodil Compounds. J. Med. Chem. 1991, 34, 3085-3090.
17. Seeburg, P. H. The Molecular Biology of Mammalian Glutamate Receptor Channels. Trends Neurosci. 1993, 16, 359-365.
18. Monyer, H.; Sprengel, R.; Schoepfer, R.; Herb, A.; Higuchi, M.; Lomeli, H.; Burnashev, N.; Sakmann, B.; Seeburg, P. Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes. Science 1992, 256, 1217-1221. Kutsuwada, T.; Kashiwabuchi, N.; Mori, H.; Sakimura, K.; Kushiya, E.; Araki, K.; Meguro, H.; Masaki, H.; Kumanishi, T.; Arakawa, M.; Mishina, M. Molecular Diversity of the NMDA Receptor Channel. Nature 1992, 358, 36-41. Chazot, P. L.; Coleman, S. K.; Cik, M.; Stephenson, F. A. Molecular Characterization of N-Methyl-D-aspartate Receptors Expressed in Mammalian Cells Yields Evidence for the Coexistence of Three Subunit Types within a Discrete Receptor Molecule. J. Biol. Chem. 1994, 269, 24403-24409.
19. Monyer, H.; Sprengel, R.; Schoepfer, R.; Herb, A.; Higuchi, M.; Lomeli, H.; Burnashev, N.; Sakmann, B.; Seeburg, P. Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes. Science 1992, 256, 1217-1221. Kutsuwada, T.; Kashiwabuchi, N.; Mori, H.; Sakimura, K.; Kushiya, E.; Araki, K.; Meguro, H.; Masaki, H.; Kumanishi, T.; Arakawa, M.; Mishina, M. Molecular Diversity of the NMDA Receptor Channel. Nature 1992, 358, 36-41. Chazot, P. L.; Coleman, S. K.; Cik, M.; Stephenson, F. A. Molecular Characterization of N-Methyl-D-aspartate Receptors Expressed in Mammalian Cells Yields Evidence for the Coexistence of Three Subunit Types within a Discrete Receptor Molecule. J. Biol. Chem. 1994, 269, 24403-24409.
20. Monyer, H.; Sprengel, R.; Schoepfer, R.; Herb, A.; Higuchi, M.; Lomeli, H.; Burnashev, N.; Sakmann, B.; Seeburg, P. Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes. Science 1992, 256, 1217-1221. Kutsuwada, T.; Kashiwabuchi, N.; Mori, H.; Sakimura, K.; Kushiya, E.; Araki, K.; Meguro, H.; Masaki, H.; Kumanishi, T.; Arakawa, M.; Mishina, M. Molecular Diversity of the NMDA Receptor Channel. Nature 1992, 358, 36-41. Chazot, P. L.; Coleman, S. K.; Cik, M.; Stephenson, F. A. Molecular Characterization of N-Methyl-D-aspartate Receptors Expressed in Mammalian Cells Yields Evidence for the Coexistence of Three Subunit Types within a Discrete Receptor Molecule. J. Biol. Chem. 1994, 269, 24403-24409.
21. Schmidt, W. J.; Bubser, M. Anticataleptic Effects of the N-Methyl-D-Aspartate Antagonist MK-801 in Rats. Pharmacol. Biochem. Behav. 1989, 32, 621-623. Mehta, A. K.; Ticku, M. K. Role of N-Methyl-D-Aspartate (NMDA) Receptors in Experimental Catalepsy in Rats. Life Sci. 1990, 209, 128-133.
22. Schmidt, W. J.; Bubser, M. Anticataleptic Effects of the N-Methyl-D-Aspartate Antagonist MK-801 in Rats. Pharmacol. Biochem. Behav. 1989, 32, 621-623. Mehta, A. K.; Ticku, M. K. Role of N-Methyl-D-Aspartate (NMDA) Receptors in Experimental Catalepsy in Rats. Life Sci. 1990, 209, 128-133.
23. For a review, see: Herrera, D. G.; Robertson, H. A. Activation of c-fos in the Brain. Prog. Neurobiol. 1996, 50, 83-107.
24. Dragunow, M.; Faull, R. L. M.; Jansen, K. L. R. MK-801, an Antagonist of NMDA Receptors, Inhibits Injury-Induced cfos Accumulation in Rat Brain. Neurosci. Lett. 1990, 109, 128-133.
25. Sonnenberg, J. L.; Mitchelmore, C.; MacGregor-Leon, P. F.; Hempstead, J.; Morgan, J. I.; Curran, T. Glutamate Receptor Agonists Increase the Expression of Fos, Fra, and AP-1 DNA Binding Activity in the Mammalian Brain. J. Neurosci. Res. 1989, 24, 72-80. Le, F.; Wilce, P. A.; Hume, D. A.; Shanley, B. C. Involvement of γ-Aminobutyric Acid and N-Methyl-D-Aspartate Receptors in the Inhibitory Effect of Ethanol on Pentylenetetrazole-Induced cfos Expression in Rat Brain. J. Neurochem. 1992, 59, 1309-1315. Sharp, J. W.; Sagar, S. M.; Hisanaga, K.; Jasper, P.; Sharp, F. R. The NMDA Receptor Mediates Cortical Induction of fos and fos-Related Antigens Following Cortical Injury. Exp. Neurol 1990, 109, 323-332.
26. Sonnenberg, J. L.; Mitchelmore, C.; MacGregor-Leon, P. F.; Hempstead, J.; Morgan, J. I.; Curran, T. Glutamate Receptor Agonists Increase the Expression of Fos, Fra, and AP-1 DNA Binding Activity in the Mammalian Brain. J. Neurosci. Res. 1989, 24, 72-80. Le, F.; Wilce, P. A.; Hume, D. A.; Shanley, B. C. Involvement of γ-Aminobutyric Acid and N-Methyl-D-Aspartate Receptors in the Inhibitory Effect of Ethanol on Pentylenetetrazole-Induced cfos Expression in Rat Brain. J. Neurochem. 1992, 59, 1309-1315. Sharp, J. W.; Sagar, S. M.; Hisanaga, K.; Jasper, P.; Sharp, F. R. The NMDA Receptor Mediates Cortical Induction of fos and fos-Related Antigens Following Cortical Injury. Exp. Neurol 1990, 109, 323-332.
27. Sonnenberg, J. L.; Mitchelmore, C.; MacGregor-Leon, P. F.; Hempstead, J.; Morgan, J. I.; Curran, T. Glutamate Receptor Agonists Increase the Expression of Fos, Fra, and AP-1 DNA Binding Activity in the Mammalian Brain. J. Neurosci. Res. 1989, 24, 72-80. Le, F.; Wilce, P. A.; Hume, D. A.; Shanley, B. C. Involvement of γ-Aminobutyric Acid and N-Methyl-D-Aspartate Receptors in the Inhibitory Effect of Ethanol on Pentylenetetrazole-Induced cfos Expression in Rat Brain. J. Neurochem. 1992, 59, 1309-1315. Sharp, J. W.; Sagar, S. M.; Hisanaga, K.; Jasper, P.; Sharp, F. R. The NMDA Receptor Mediates Cortical Induction of fos and fos-Related Antigens Following Cortical Injury. Exp. Neurol 1990, 109, 323-332.
28. Nellgard, B.; Weiloch, T. NMDA-Receptor Blockers But Not NBQX, an AMPA Receptor Antagonist, Inhibit Spreading Depression in Rat Brain. Acta Physiol. Scand. 1992, 146, 467-503.
29. Lauritzen, M. Pathophysiology of the Migraine Aura: The Spreading Depression Theory. Brain 1994, 117, 199-210.
30. The conformation of 1 has been calculated and compared to that obtained by X-ray analysis (see ref 3). The conformations are essentially identical. Furthermore, the solution conformation of 1 (and its erythro diastereomer) can be approximated by application of the Karplus equation to the NMR coupling constants for the benzylic proton.
31. Nishikawa, M.; Kanno, M.; Kuriki, H.; Sugihara, H.; Motohashi, M.; Itoh, K.; Miyashita, O.; Oka, Y.; Sanno, Y. Selective β-Adrenoceptor Activities of Tetrahydronaphthalene Derivatives. Life Sci. 1975, 16, 305-314. For a separate study on adrenergic activity of the trans-tetrahydronaphthols, see: Macchia, B.; Balsamo, A.; Breschi, M. C.; Lapucci, A.; Lucacchini, A.; Macchia, F.; Manera, C.; Martinelli, A.; Martini, C.; Martinotti, E.; Nencetti, S. Conformational Effects on the Activity of Drugs. 13. A revision of Previously Proposed Models for the activation of α- and β-Adrenergic Receptors. J. Med. Chem. 1992, 35, 1009-1018.
32. Nishikawa, M.; Kanno, M.; Kuriki, H.; Sugihara, H.; Motohashi, M.; Itoh, K.; Miyashita, O.; Oka, Y.; Sanno, Y. Selective β-Adrenoceptor Activities of Tetrahydronaphthalene Derivatives. Life Sci. 1975, 16, 305-314. For a separate study on adrenergic activity of the trans-tetrahydronaphthols, see: Macchia, B.; Balsamo, A.; Breschi, M. C.; Lapucci, A.; Lucacchini, A.; Macchia, F.; Manera, C.; Martinelli, A.; Martini, C.; Martinotti, E.; Nencetti, S. Conformational Effects on the Activity of Drugs. 13. A revision of Previously Proposed Models for the activation of α- and β-Adrenergic Receptors. J. Med. Chem. 1992, 35, 1009-1018.
33. Lal, B.; Khanna, J. M.; Anand, N. Phenethylamine in a Rigid Framework. 2,3-Substituted cis- and trans-6-Amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ols. J. Med. Chem. 1971, 15, 23-27.
34. Meldrum, B. Possible Therapeutic Application of Antagonists of Excitatory Amino Acid Neurotransmitters. Clin. Sci. 1985, 68, 113-122. Greenamyre, J. T. The Role of Glutamate in Neurotransmission and in Neurologic Disease. Arch. Neurol. 1986, 43,1058-1063. Choi, D. W. Glutamate Neurotoxicity and Diseases of the Central Nervous System. Neuron 1988, 1, 623-634. Danysz, W.; Parsons, C. F.; Bresink, I.; Quack, G. Glutamate in CNS Disorders. DN&P 1995, 8, 261-277.
35. Meldrum, B. Possible Therapeutic Application of Antagonists of Excitatory Amino Acid Neurotransmitters. Clin. Sci. 1985, 68, 113-122. Greenamyre, J. T. The Role of Glutamate in Neurotransmission and in Neurologic Disease. Arch. Neurol. 1986, 43,1058-1063. Choi, D. W. Glutamate Neurotoxicity and Diseases of the Central Nervous System. Neuron 1988, 1, 623-634. Danysz, W.; Parsons, C. F.; Bresink, I.; Quack, G. Glutamate in CNS Disorders. DN&P 1995, 8, 261-277.
36. Meldrum, B. Possible Therapeutic Application of Antagonists of Excitatory Amino Acid Neurotransmitters. Clin. Sci. 1985, 68, 113-122. Greenamyre, J. T. The Role of Glutamate in Neurotransmission and in Neurologic Disease. Arch. Neurol. 1986, 43,1058-1063. Choi, D. W. Glutamate Neurotoxicity and Diseases of the Central Nervous System. Neuron 1988, 1, 623-634. Danysz, W.; Parsons, C. F.; Bresink, I.; Quack, G. Glutamate in CNS Disorders. DN&P 1995, 8, 261-277.
37. Meldrum, B. Possible Therapeutic Application of Antagonists of Excitatory Amino Acid Neurotransmitters. Clin. Sci. 1985, 68, 113-122. Greenamyre, J. T. The Role of Glutamate in Neurotransmission and in Neurologic Disease. Arch. Neurol. 1986, 43,1058-1063. Choi, D. W. Glutamate Neurotoxicity and Diseases of the Central Nervous System. Neuron 1988, 1, 623-634. Danysz, W.; Parsons, C. F.; Bresink, I.; Quack, G. Glutamate in CNS Disorders. DN&P 1995, 8, 261-277.
38. Muir, K. W.; Lees, K. R. Clinical Experience with Excitatory Amino Acid Antagonist Drugs. Stroke 1995, 26, 503-513. McCulloch, J. Glutamate Receptor Antagonists in Cerebral Ischemia. J. Neural Transm. 1994, 43 (Suppl.), 71-79. Albers, G. W.; Goldberg, M. P.; Choi, D. W. N-Methyl-D-Aspartate Antagonists: Ready for Clinical Trial in Brain Ischemia? Ann. Neurol. 1989, 25, 398-403.
39. Muir, K. W.; Lees, K. R. Clinical Experience with Excitatory Amino Acid Antagonist Drugs. Stroke 1995, 26, 503-513. McCulloch, J. Glutamate Receptor Antagonists in Cerebral Ischemia. J. Neural Transm. 1994, 43 (Suppl.), 71-79. Albers, G. W.; Goldberg, M. P.; Choi, D. W. N-Methyl-D-Aspartate Antagonists: Ready for Clinical Trial in Brain Ischemia? Ann. Neurol. 1989, 25, 398-403.
40. Muir, K. W.; Lees, K. R. Clinical Experience with Excitatory Amino Acid Antagonist Drugs. Stroke 1995, 26, 503-513. McCulloch, J. Glutamate Receptor Antagonists in Cerebral Ischemia. J. Neural Transm. 1994, 43 (Suppl.), 71-79. Albers, G. W.; Goldberg, M. P.; Choi, D. W. N-Methyl-D-Aspartate Antagonists: Ready for Clinical Trial in Brain Ischemia? Ann. Neurol. 1989, 25, 398-403.
41. McIntosh, T. K. Novel Pharmacologic Therapies in the Treatment of Experimental Traumatic Brain Injury: A Review. J. Neurotrauma 1993, 10, 215-261.
42. Meldrum, B. The Role of Glutamate in Epilepsy and Other CNS Disorders. Neurology 1994, 44 (Suppl. 8), S14-S23.
43. Greenamyre, J. T.; O'Brian, C. F. N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease. Arch. Neurol. 1991, 48, 977-981. Starr, M. S. Glutamate/Dopamine D1/D2 Balance in the Basal Ganglia and Its Relevance to Parkinson's Disease. Synapse 1995, 19, 264-293.
44. Greenamyre, J. T.; O'Brian, C. F. N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease. Arch. Neurol. 1991, 48, 977-981. Starr, M. S. Glutamate/Dopamine D1/D2 Balance in the Basal Ganglia and Its Relevance to Parkinson's Disease. Synapse 1995, 19, 264-293.
45. Greenamyre, J. T.; Penney, J. B.; Young, A. B.; D'Amato, C. J.; Hicks, S. P.; Shoulson, I. Alterations in L-Glutamate Binding in Alzheimer's and Huntington's Diseases. Science 1985, 227, 1496-1498. Young, A. B.; Greenamyre, J. T.; Hollingsworth, Z.; Albin, R.; D'Amato, C.; Shoulson, I.; Penney, J. B. NMDA Receptor Losses in Putamen from Patients with Huntington's Disease. Science 1988, 241, 981-983.
46. Greenamyre, J. T.; Penney, J. B.; Young, A. B.; D'Amato, C. J.; Hicks, S. P.; Shoulson, I. Alterations in L-Glutamate Binding in Alzheimer's and Huntington's Diseases. Science 1985, 227, 1496-1498. Young, A. B.; Greenamyre, J. T.; Hollingsworth, Z.; Albin, R.; D'Amato, C.; Shoulson, I.; Penney, J. B. NMDA Receptor Losses in Putamen from Patients with Huntington's Disease. Science 1988, 241, 981-983.
47. Dickenson, A. H. Spinal Cord Pharmacology of Pain. Br. J. Anaesth. 1995, 75, 193-200.
48. For an overview and leading references to the wind up phenomenon and the potential use of NMDA antagonists as analgesics, see: Dickenson, A. H. A Cure for Wind Up: NMDA Receptor Antagonists as Potential Analgesics. Trends Pharmacol. Sci. 1990, 11, 307-309.
49. Herrara, D. G.; Robertson, H. A. Application of Potassium Chloride to the Brain Surface induces the c-fos Proto-Oncogene: Reversal by MK-801. Brain Res. 1990, 570, 166-170. Lauritzen, M. Spreading Depression and Migraine. Path. Biol. 1992, 40, 332-337. Lauritzen, M. Pathophysiology of the Migraine Aura. Brain 1994, 117, 199-210.
50. Herrara, D. G.; Robertson, H. A. Application of Potassium Chloride to the Brain Surface induces the c-fos Proto-Oncogene: Reversal by MK-801. Brain Res. 1990, 570, 166-170. Lauritzen, M. Spreading Depression and Migraine. Path. Biol. 1992, 40, 332-337. Lauritzen, M. Pathophysiology of the Migraine Aura. Brain 1994, 117, 199-210.
51. Herrara, D. G.; Robertson, H. A. Application of Potassium Chloride to the Brain Surface induces the c-fos Proto-Oncogene: Reversal by MK-801. Brain Res. 1990, 570, 166-170. Lauritzen, M. Spreading Depression and Migraine. Path. Biol. 1992, 40, 332-337. Lauritzen, M. Pathophysiology of the Migraine Aura. Brain 1994, 117, 199-210.
52. For leading references, see: Liljequist, S. The Competitive NMDA Receptor Antagonist, CGP 39551, Inhibits Ethanol Withdrawal Seizures. Eur. J. Pharmacol. 1991, 192, 197-198.
53. Trujillo, K. A.; Akil, H. Inhibition of Morphine Tolerance and Dependence by the NMDA Receptor Antagonist MK-801. Science 1991, 251, 85-87.
54. Deutsch, S. I.; Mastropaolo, J.; Schwartz, B. L.; Rosse, R. B.; Morihisa, J. M. A "Glutamatergic Hypothesis" of Schizophrenia. Clin. Neuropharmacol. 1989, 12, 1-13. Sherman, A. D.; Davidson, A. T.; Baruah, S.; Hegwood, T. S.; Waziri, R. Evidence of Glutamatergic Deficiency in Schizophrenia. Neurosci. Lett. 1991, 121, 77-80.
55. Deutsch, S. I.; Mastropaolo, J.; Schwartz, B. L.; Rosse, R. B.; Morihisa, J. M. A "Glutamatergic Hypothesis" of Schizophrenia. Clin. Neuropharmacol. 1989, 12, 1-13. Sherman, A. D.; Davidson, A. T.; Baruah, S.; Hegwood, T. S.; Waziri, R. Evidence of Glutamatergic Deficiency in Schizophrenia. Neurosci. Lett. 1991, 121, 77-80.
56. Personal communication from Dr. S. Jaw. Details will be published elsewhere.
57. Koch, K.; Biggers, M. S. General Preparation of 7-Substituted 4-Chromanones: Synthesis of a Potent Aldose Reductase Inhibitor. J. Org. Chem. 1994, 59, 1216-1218.
58. Schlegel, H. B. Optimization of Equilibrium Geometries and Transition Structures. J. Comput Chem. 1982, 3, 214-218.
59. Francl, M. M.; Pietro, W. J.; Hehre, W. J.; Binkley, J. S.; Gordon, M. S.; DeFrees, D. J.; Pople, J. A. Self-Consistent Molecular Orbital Methods. XXIII. A Polarization-Type Basis Set for Second-Row Elements. J. Chem. Phys. 1982, 77, 3654-3665.
60. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, L.; Fox, D. J.; Binkley, J. S.; DeFrees, D. J.; Baker, J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. Gaussian 94, Revision B.3; Gaussian, Inc.: Pittsburgh, PA, 1995.
61. Stühmer, W. Electrophysiological recordings from Xenopus oocytes. Methods Enzymol. 1992, 207, 319-339. Sands, S. B.; Costa, A. C. S.; Patrick, J. W. Barium permeability of neuronal nicotinic receptor α7 expressed in Xenopus oocytes. Biophys. J. 1993, 65, 2614-2621.
62. Stühmer, W. Electrophysiological recordings from Xenopus oocytes. Methods Enzymol. 1992, 207, 319-339. Sands, S. B.; Costa, A. C. S.; Patrick, J. W. Barium permeability of neuronal nicotinic receptor α7 expressed in Xenopus oocytes. Biophys. J. 1993, 65, 2614-2621.